Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes

计划入组 20 人 · 首次发布于 2015 年 9 月 29 日

Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome

首次发布于 2014 年 7 月 15 日

Treatment Use of 3,4-Diaminopyridine

首次发布于 2013 年 1 月 10 日

Amifampridine(Firdapse, Ruzurgi, Firdapse (previously Zenas), Amifampridine SERB)

C₅H₇N₃ · Rx

sodium pancratistatin 3,4-cyclic phosphate

3,4-dimethylaniline

C₈H₁₁N

Iceni Gold Ltd

HEC CJ PHARM

Hong Kong, China

ZHEJIANG HUAHAI PHARMACEUTICAL CO.,LTD.

Sironax Strengthens Leadership Team with Two Senior Appointments to Advance Age-Related Disease Pipeline

Catalyst Pharmaceuticals Secures Patent Settlement with Teva, Extending Firdapse Market Exclusivity Until 2035

FDA Updates Fludarabine Phosphate Labeling for CLL Treatment